Cargando…
Comment on ‘Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety’
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245373/ https://www.ncbi.nlm.nih.gov/pubmed/34037974 http://dx.doi.org/10.1007/s40261-021-01043-4 |
| _version_ | 1783716102006636544 |
|---|---|
| author | Koren, Andrew Karas, Andreas Echols, Roger |
| author_facet | Koren, Andrew Karas, Andreas Echols, Roger |
| author_sort | Koren, Andrew |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8245373 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82453732021-07-14 Comment on ‘Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety’ Koren, Andrew Karas, Andreas Echols, Roger Clin Drug Investig Letter to the Editor Springer International Publishing 2021-05-26 2021 /pmc/articles/PMC8245373/ /pubmed/34037974 http://dx.doi.org/10.1007/s40261-021-01043-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Letter to the Editor Koren, Andrew Karas, Andreas Echols, Roger Comment on ‘Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety’ |
| title | Comment on ‘Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety’ |
| title_full | Comment on ‘Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety’ |
| title_fullStr | Comment on ‘Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety’ |
| title_full_unstemmed | Comment on ‘Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety’ |
| title_short | Comment on ‘Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety’ |
| title_sort | comment on ‘cefiderocol, a new siderophore cephalosporin for the treatment of complicated urinary tract infections caused by multidrug-resistant pathogens: preclinical and clinical pharmacokinetics, pharmacodynamics, efficacy and safety’ |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245373/ https://www.ncbi.nlm.nih.gov/pubmed/34037974 http://dx.doi.org/10.1007/s40261-021-01043-4 |
| work_keys_str_mv | AT korenandrew commentoncefiderocolanewsiderophorecephalosporinforthetreatmentofcomplicatedurinarytractinfectionscausedbymultidrugresistantpathogenspreclinicalandclinicalpharmacokineticspharmacodynamicsefficacyandsafety AT karasandreas commentoncefiderocolanewsiderophorecephalosporinforthetreatmentofcomplicatedurinarytractinfectionscausedbymultidrugresistantpathogenspreclinicalandclinicalpharmacokineticspharmacodynamicsefficacyandsafety AT echolsroger commentoncefiderocolanewsiderophorecephalosporinforthetreatmentofcomplicatedurinarytractinfectionscausedbymultidrugresistantpathogenspreclinicalandclinicalpharmacokineticspharmacodynamicsefficacyandsafety |